
Xencor (XNCR) Stock Forecast & Price Target
Xencor (XNCR) Analyst Ratings
Bulls say
Xencor is poised for growth in the coming years with several promising pipeline products, including XmAb819 and XmAb541, which have demonstrated strong response rates in heavily pretreated ccRCC and ovarian cancer patients, respectively. The recent 2Q26 earnings report, which showed solid progress and updates on their key pipeline programs, is a positive indication of the company's potential. With a diverse revenue stream and strategic collaborations and partnerships, Xencor has a strong financial standing to support its research and development efforts for these novel antibody therapeutics.
Bears say
Xencor is showing positive signs with its strong 2Q26 EPS of $(0.29), ahead of analyst expectations of $(0.83), due to increased Ultomiris royalty revenue and a milestone payment from Zenas. The company's increased YE26 cash guidance of $420-440MM and reiterated runway through 2028 are also promising, with support from the recent settlement and milestone payments. Overall, Xencor has a promising pipeline with multiple upcoming catalysts, making it a company to watch in the biopharmaceutical industry.
This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.
Xencor (XNCR) Analyst Forecast & Price Prediction
Start investing in Xencor (XNCR)
Order type
Buy in
Order amount
Est. shares
0 shares